Venus-Neo, expandable dry-tissue valve, completes its first case in FIM clinical trial

On April 12th, 2022, Venus Medtech (Hangzhou) Inc. ("Venus Medtech", 02500.HK), a leading platform company for innovative structural heart disease therapies in China, announced?the recent completion of the global first implantation in the First-in-Man (FIM) clinical trial of Venus-Neo,?its self-developed next-generation expandable bioprosthetic dry-tissue valve,?in?Union Hospital of Tongji Medical College, Huazhong University of Science and Technology ("Wuhan Union").?

This is another next-generation dry-tissue valve developed by Venus Medtech that has been put into clinical studies apart from Venus-Vitae and Venus PowerX. It extends the durability of bioprosthetic valve, helps to achieve Venus Medtech’s overall layout of aortic valve disease solutions, and consolidates the company's position as a leader in heart valve disease treatment in China.

The procedure was completed by?a?multidisciplinary team comprising Professor Dong Nianguo, Director of Cardiovascular Surgery Department at Wuhan Union, as well as Professor Liu Junwei and Professor Wang Yin.